Dr. Martens (LON:DOCS) Trading Up 1.6% - Should You Buy?

Key Points

• Dr. Martens shares rose 1.6% to GBX 83.49 in midday trading, though volume was approximately 90% below the average session level.
• Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of GBX 105, implying potential upside from the current price.
• The company reported quarterly EPS of GBX 4.20 and revenue of £764.9 million. Insiders also purchased approximately 300,199 shares in the past 90 days, while the stock trades at a PE ratio of 34.79 and carries relatively high leverage.

Dr. Martens plc (LON:DOCS - Get Free Report)'s stock price shot up 1.6% during mid-day trading on Friday . The stock traded as high as GBX 83.80 and last traded at GBX 83.49. 740,729 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 7,520,830 shares. The stock had previously closed at GBX 82.20.

Wall Street Analyst Weigh In

DOCS has been the topic of a number of research reports. Royal Bank Of Canada restated a "sector perform" rating and set a GBX 100 price target on shares of Dr. Martens in a research report on Tuesday, June 2nd. Berenberg Bank lowered their price objective on shares of Dr. Martens from GBX 114 to GBX 110 and set a "buy" rating for the company in a report on Tuesday, May 19th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of GBX 105.

Dr. Martens Stock Performance

The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13. The stock has a market cap of £799.13 million, a PE ratio of 34.79, a price-to-earnings-growth ratio of 6.40 and a beta of 0.24. The business has a 50 day moving average price of GBX 73.70 and a two-hundred day moving average price of GBX 69.01.

Dr. Martens (LON:DOCS - Get Free Report) last issued its earnings results on Tuesday, May 19th. The company reported GBX 4.20 EPS for the quarter. The company had revenue of £764.90 million for the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. As a group, equities research analysts forecast that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Insider Transactions at Dr. Martens

In other news, insider Ije Nwokori acquired 118,516 shares of the stock in a transaction dated Thursday, June 25th. The stock was purchased at an average cost of GBX 72 per share, with a total value of £85,331.52. Also, insider Giles Wilson bought 68,313 shares of the company's stock in a transaction dated Thursday, June 25th. The shares were purchased at an average price of GBX 72 per share, with a total value of £49,185.36. Insiders acquired 300,199 shares of company stock worth $22,061,408 in the last 90 days. Corporate insiders own 2.94% of the company's stock.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source